Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Sensor Enabled Affective Computing for Enhancing Medical Care

SenseCare

This project brings together a diverse group of subject matter experts from industry and academia under one umbrella, with the main aim of enhancing and advancing future healthcare processes and systems using sensory and machine learning technologies to provide emotional (affective) and cognitive insights into patients well-being so as to provide...

Funding Programme
Start Date
End Date
Total Funding
€ 504 000
European Countries Involved

siRNA-based therapy for cerebral tauopathies

SITAU

Neurodegenerative disorders are an increasing healthcare problem. Many of these diseases are characterized by aggregation of proteins, which leads to neuronal dysregulation and cell death. Neurofibrillary tangles, pathological aggregates of tau protein, are the characteristic neuropathological stigmata defining a group of disorders termed...

Funding Programme
Start Date
End Date
Total Funding
€ 158 695
European Countries Involved

Small molecule stabilizers of 14-3-3 Protein-Protein Interactions as novel drugs in cancer and neurodegenerative diseases

14-3-3Stabs

The objective of the application is the development and characterization of small molecule stabilizers of protein-protein interactions (“Molecular Glues”) as a novel class of biological tool compounds and potential therapeutic drugs for the treatment of cancer as well as Alzheimer’s and Parkinson’s Disease, respectively. As biological targets we...

Funding Programme
Start Date
End Date
Total Funding
€ 2 008 622
European Countries Involved

Small vessel diseases in a mechanistic perspective: Targets for Intervention Affected pathways and mechanistic exploitation for prevention of stroke and dementia

SVDs-at-target

Stroke and dementia rank among the most pressing health issues in Europe. Cerebral small vessel diseases (SVDs) have emerged as a central link between these two major co-morbidities. SVDs account for more than 30% of strokes and at least 40% of dementia cases. They encounter multiple distinct diseases that can be separated based on their underlying...

Funding Programme
Start Date
End Date
Total Funding
€ 5 998 300
European Countries Involved

Social Health And Reserve in the Dementia patient journey

SHARED

The role of social health in onset, disease course and prognosis of dementia remains underexplored. Social health has been conceptualized as the influence of social resources in finding a balance between capacities and limitations. Moreover, social health affects and is affected by biological processes that underlie the dementia syndrome. This...

Funding Programme
Start Date
End Date
European Countries Involved

Space coding in hippocampo-entorhinal neuronal assemblies

SPACEBRAIN

Despite impressive advances in almost every field of neuroscience, our insights into brain function remain largely confined to its building blocks at the microscopic level, and to phenomenological descriptions at the macroscopic level. Understanding how complex mental functions originate from electrical and chemical processes in brain cells...

Funding Programme
Start Date
End Date
Total Funding
€ 7 996 767
European Countries Involved

STED-enabled super-resolution multimode-fibre based holographic endoscopy for deep-tissue observations of neuronal connectivity

STEDGate

Neurological disorders have emerged as a significant global societal burden, exemplified by afflictions like Alzheimer's and Parkinson's, impacting over one billion individuals globally and surpassing the combined economic burden of cancer and diabetes. This has spurred a concerted global effort, with increased support for neuroscience research...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions

SMASH-HCM

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death among young athletes. Comorbidities due to gene mutations include altered vascular...

Funding Programme
Start Date
End Date
Total Funding
€ 8 546 366
European Countries Involved

Subjective cognitive decline in preclinical Alzheimer’s Disease: European initiative on harmonization and on a lifestyle-based prevention strategy

EURO-SCD

Subjective cognitive decline (SCD) in elderly individuals with still normal cognitive performance is considered an at-risk condition of Alzheimer's disease (AD) dementia and may reflect its first symptomatic manifestation. This makes SCD a promising target for dementia prevention trials. This project aims at creating a transnational, harmonized...

Funding Programme
Start Date
End Date
Total Funding
€ 834 697
European Countries Involved

Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

2D-BioPAD

2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Funding Programme
Start Date
End Date
Total Funding
€ 5 957 949
European Countries Involved

SUstainable PROduction of GALanthamine by both in vitro and agricultural crops of highly galanthamine-containing plants

SUPROGAL

Galanthamine is an alkaloid produced exclusively by plants of the family Amaryllidaceae, mainly belonging to the genus Galanthus, Leucojum and Narcissus. Owing to its acetylcholinesterase inhibitory activity, galanthamine is used and marketed for the treatment of the Alzheimer’s disease, among others. Although it is obtained by organic synthesis...

Funding Programme
Start Date
End Date
Total Funding
€ 1 343 680
European Countries Involved

Synapse-to-nucleus communication in Alzheimer’s disease

STAD

Understanding how fast events at synapses are converted into long-lasting changes of neuronal acti- vity is a very important question in neuroscience. Several recent studies demonstrated that synapses and nuclei are connected by bidirectional communication routes that enable the efficient transfer of information and regulate the long-term...

Funding Programme
Start Date
End Date
Total Funding
€ 838 087
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).